These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 18371162)
1. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma. Livnat T; Martinowitz U; Zivelin A; Seligsohn U Haemophilia; 2008 Jul; 14(4):782-6. PubMed ID: 18371162 [TBL] [Abstract][Full Text] [Related]
2. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. Martinowitz U; Livnat T; Zivelin A; Kenet G Haemophilia; 2009 Jul; 15(4):904-10. PubMed ID: 19473416 [TBL] [Abstract][Full Text] [Related]
3. Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma. Klintman J; Astermark J; Berntorp E Br J Haematol; 2010 Nov; 151(4):381-6. PubMed ID: 20977448 [TBL] [Abstract][Full Text] [Related]
4. Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions. Aljamali MN; Kjalke M; Hedner U; Ezban M; Tranholm M Haemophilia; 2009 Nov; 15(6):1318-26. PubMed ID: 19659796 [TBL] [Abstract][Full Text] [Related]
5. Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors--a thrombin generation-guided pilot study. Livnat T; Martinowitz U; Azar-Avivi S; Zivelin A; Brutman-Barazani T; Lubetsky A; Kenet G Haemophilia; 2013 Sep; 19(5):782-9. PubMed ID: 23659442 [TBL] [Abstract][Full Text] [Related]
6. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Turecek PL; Váradi K; Keil B; Negrier C; Berntorp E; Astermark J; Bordet JC; Morfini M; Linari S; Schwarz HP Pathophysiol Haemost Thromb; 2003; 33(1):16-22. PubMed ID: 12853708 [TBL] [Abstract][Full Text] [Related]
7. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone. Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255 [TBL] [Abstract][Full Text] [Related]
8. The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents. van Veen JJ; Gatt A; Bowyer AE; Cooper PC; Kitchen S; Makris M Int J Lab Hematol; 2009 Apr; 31(2):189-98. PubMed ID: 18190585 [TBL] [Abstract][Full Text] [Related]
9. Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A. Klintman J; Berntorp E; Astermark J; Haemophilia; 2010 Jan; 16(1):e210-5. PubMed ID: 19878339 [TBL] [Abstract][Full Text] [Related]
10. General haemostatic agents--fact or fiction? Hedner U Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145 [TBL] [Abstract][Full Text] [Related]
11. Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for haemophilia patients with inhibitors undergoing major orthopaedic surgeries. Bonnet PO; Yoon BS; Wong WY; Boswell K; Ewenstein BM Haemophilia; 2009 Sep; 15(5):1083-9. PubMed ID: 19456876 [TBL] [Abstract][Full Text] [Related]
12. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa. Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927 [TBL] [Abstract][Full Text] [Related]
13. A highly sensitive thrombin generation assay for assessment of recombinant activated factor VII therapy in haemophilia patients with an inhibitor. Livnat T; Martinowitz U; Zivelin A; Rima D; Kenet G Thromb Haemost; 2011 Apr; 105(4):688-95. PubMed ID: 21225093 [TBL] [Abstract][Full Text] [Related]
14. Effect of heparins on thrombin generation in hemophilic plasma supplemented with FVIII, FVIIa, or FEIBA. Parmar N; Berry LR; Paredes N; Chan AK Clin Lab; 2005; 51(3-4):157-66. PubMed ID: 15819171 [TBL] [Abstract][Full Text] [Related]
15. Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors. Qi X; Zhao Y; Li K; Fan L; Hua B Blood Coagul Fibrinolysis; 2014 Oct; 25(7):754-60. PubMed ID: 24806320 [TBL] [Abstract][Full Text] [Related]
16. Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma. Szlam F; Taketomi T; Sheppard CA; Kempton CL; Levy JH; Tanaka KA Anesth Analg; 2008 Mar; 106(3):719-24, table of contents. PubMed ID: 18292408 [TBL] [Abstract][Full Text] [Related]
17. Ex vivo reversal of the anticoagulant effects of edoxaban. Halim AB; Samama MM; Mendell J Thromb Res; 2014 Oct; 134(4):909-13. PubMed ID: 25179520 [TBL] [Abstract][Full Text] [Related]
18. Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. Dargaud Y; Lienhart A; Meunier S; Hequet O; Chavanne H; Chamouard V; Marin S; Negrier C Haemophilia; 2005 Sep; 11(5):552-8. PubMed ID: 16128902 [TBL] [Abstract][Full Text] [Related]
19. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses. Kjalke M; Kjelgaard-Hansen M; Andersen S; Hilden I J Thromb Haemost; 2021 Jul; 19(7):1687-1696. PubMed ID: 33819375 [TBL] [Abstract][Full Text] [Related]
20. Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI. Livnat T; Zivelin A; Martinowitz U; Salomon O; Seligsohn U J Thromb Haemost; 2006 Jan; 4(1):192-200. PubMed ID: 16409469 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]